GET DAILY SIGNALSXilio Therapeutics (XLO) Falls -11.5% Over 30 Days Following Weiss Ratings Downgrade
Key Takeaways
- Xilio Therapeutics (XLO) fell roughly 11.5% over the 30 days through late October 2026, declining from about $9.05 to approximately $8.01.
- The decline was concentrated in the second half of October, punctuated by a Weiss Ratings downgrade to a "Sell" rating on October 23, 2026.
- Over the last quarter, the stock traded mostly range-bound between about $8.80 and $9.50 before the recent sell-off, leaving it broadly lower for the period.
- Xilio is a clinical-stage biotechnology company developing masked immuno-oncology therapies, supported by collaboration and license agreements with AbbVie (ABBV) and Gilead Sciences (GILD).
- The company reported second-quarter 2026 results that exceeded consensus estimates and held roughly $136 million in cash with an anticipated runway into early 2028.
- For deeper data on this ticker, explore its Price Targets, Earnings, and Forecast pages.
Company Overview: Xilio Therapeutics' Focus on Masked Immuno-Oncology
Xilio Therapeutics is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, focused on discovering and developing masked immuno-oncology therapies. Its proprietary masking technology is designed to keep therapeutic agents inactive in healthy tissue and selectively activate them within the tumor microenvironment, aiming to deliver durable efficacy while reducing the systemic side effects often associated with conventional cancer immunotherapies. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The company's pipeline includes XTX501, a bispecific PD-1/masked IL-2 candidate being evaluated in metastatic non-small cell lung cancer and select advanced solid tumors; efarindodekin alfa, a masked IL-12 in a Phase 2 trial; and vilastobart, a tumor-activated anti-CTLA-4 antibody. Xilio has also advanced masked T cell engager programs targeting antigens such as CLDN18.2, PSMA, and STEAP1. Strategic collaborations with AbbVie and Gilead Sciences provide non-dilutive funding and validation of the platform, which is a key reason investors follow the stock.
Stock Price Performance Over the Past 30 Days and Quarter
Over the 30 days ending in late October 2026, XLO shares declined approximately 11.5%, moving from a closing price of about $9.05 to roughly $8.01. The move was not linear: the stock held near the $9.00 level through most of September and early October before selling off sharply beginning in mid-October. The stock closed as low as $7.31 on October 26 before rebounding to about $8.01 in the following session. From what I see, this kind of volatility is common in small-cap biotech names with lighter trading volume.
The quarterly picture tells a similar but more measured story. For much of the prior three months, XLO traded in a relatively narrow band between roughly $8.80 and $9.50, reflecting limited near-term catalysts and generally light trading volume. Because most of the downside occurred in the final weeks of the period, the quarterly decline is largely a reflection of the recent 30-day move rather than a steady multi-month downtrend.
What Drove the Recent 30-Day Decline in XLO
The most concrete catalyst behind the late-October decline was a ratings action. On October 23, 2026, Weiss Ratings downgraded Xilio Therapeutics to a "Sell" rating, and the stock fell approximately 5.7% that session. The move came amid a period of thin trading volume, which can amplify price swings in a small-cap, clinical-stage name with a relatively modest float.
Broader sentiment also played a role. Small-cap biotechnology stocks remain sensitive to shifts in risk appetite, and XLO's low average daily volume makes it prone to outsized moves on comparatively modest selling pressure. The decline occurred despite second-quarter 2026 results reported in August that beat consensus estimates, with a narrower-than-expected net loss and collaboration revenue above analyst projections, suggesting the recent pressure was driven more by sentiment and rating dynamics than by a deterioration in fundamentals.
Quarterly Performance and Underlying Fundamentals
Across the broader quarter, XLO traded in a sideways range as investors weighed the company's pipeline progress against its early-stage, pre-revenue status. The period was framed by execution milestones announced earlier in 2026, including a 1-for-14 reverse stock split completed in March 2026, an IND filing for XTX501 planned for mid-2026, and continued progress across its masked T cell engager programs.
Fundamentally, Xilio's financial position remained stable through the quarter. The company reported about $136 million in cash and cash equivalents as of June 30, 2026, and extended its anticipated cash runway into the first quarter of 2028. Collaboration revenue tied to the AbbVie and Gilead agreements continued to grow year over year. Against this backdrop, the stock's late-quarter decline appears more reflective of short-term rating and sentiment pressure than any single fundamental setback.
Key Catalysts Investors Should Monitor for XLO
Investors tracking XLO should monitor several near-term catalysts. The company's next quarterly earnings report is a key checkpoint for collaboration revenue, expense trends, and updated cash-runway guidance. Progress on the XTX501 program—including the planned mid-2026 IND submission and subsequent clinical enrollment—represents a central driver of pipeline value. In my view, these milestones will likely set the tone for sentiment in the months ahead.
Additionally, milestone and option-related developments under the AbbVie and Gilead agreements, including the anticipated delivery of a Phase 1/2 option data package for efarindodekin alfa to Gilead in the first half of 2027, could influence sentiment. Broader factors such as biotech sector risk appetite, small-cap liquidity, and any further analyst ratings changes also merit attention, given the stock's sensitivity to these dynamics.
Using Tickeron AI Tools in My Research Process
When analyzing names like XLO, I frequently turn to Tickeron’s AI Trend Prediction Engine to gauge potential directional moves based on historical patterns and current data. It helps me quickly compare signals across similar biotech stocks without sifting through endless charts manually. This approach has become a regular part of how I evaluate volatility and timing in clinical-stage companies.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
XLO in upward trend: price may jump up because it broke its lower Bollinger Band on October 22, 2026
XLO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 40 cases where XLO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLO advanced for three days, in 158 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XLO as a result. In 90 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for XLO turned negative on October 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 46 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
XLO moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XLO crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for XLO entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.729) is normal, around the industry mean (3.037). P/E Ratio (-25.031) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (2.000) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. XLO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement